Avastin, which is not available in single-dose vials, has been shown to be a cost-effective treatment for macular degeneration. Lucentis, an FDA-approved treatment for macular degeneration, costs approximately $2,000, compared to $50 for Avastin. However, the additional handling (because it is not available in single-dose vials) exposes patients to potential contamination.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Four patients also suffered infections after receiving Avastin at Nashville (Tenn.) VA Medical Center. In addition, the FDA issued an alert that the drug caused at least a dozen serious eye infections in the Miami area.
The VA department said the Los Angeles medical center will cease use of Avastin and begin using Lucentis.
Related Articles on Avastin:
FDA: Repackaged Avastin Caused Eye Infections in Florida
Four Patients Become Victims of Contaminated Shots at Tennessee VA Facility
NHIC Limits Avastin Use Starting Feb. 1
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
